AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATAI

Craig Kevin James sold (to issuer) 8,437 shares of ATAI

Craig Kevin James (Chief Medical Officer) sold (to issuer) 8,437 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Original reporting
SEC EDGAR · Craig Kevin James
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATAI
Bearish
medium confidence
Mentioned
$ATAI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAIBearishLow
01

Why it matters

The insider's exit may be interpreted as a negative signal, but the modest share count and lack of price data reduce its trading relevance.

02

Market read

A routine insider sale with limited material impact; unlikely to drive significant price movement.

03

What to watch

Absence of price information and the insider's role may limit the signal's strength.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions. This filing reports a complete divestiture by the Chief Medical Officer.

Company-level read

Ticker impact

$ATAIBearishMedium confidence
Context

Chief Medical Officer Craig Kevin James sold his remaining 8,437 shares, leaving zero holdings after the transaction.

Expected impact

Modest short‑term dip or flat trading as the market digests the complete exit of the insider.

Evidence & confidence

The sale size is modest for a micro‑cap biotech and the price was not disclosed, limiting material impact.

Market effects

Sector

Minimal effect on the broader biotech sector; insider sales are common and rarely move the sector.

Regional

No regional impact; the filing is specific to the company.

Global

Low global relevance; limited to ATAI investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Company
    AtaiBeckley Inc.

    Biotech firm developing psychedelic therapies.

  • Individual
    Craig Kevin James

    Chief Medical Officer of ATAI.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATAI insider trading history →

Related articles

SEP 11
$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

vocal.media3 min
SEP 11
$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

blockonomi.com2 min
SEP 11
$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

citybiz.co2 min
SEP 11
$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.

minichart.com.sg2 min